Novo Holdings has reported significant progress in its Asian investments throughout 2024, focusing on healthcare, life sciences, and planetary health. The company, which manages the assets of the Novo Nordisk Foundation, has expanded its presence in key markets, including Singapore, Shanghai, and soon Mumbai. This expansion is part of Novo Holdings’ strategy to foster long-term partnerships that yield both financial returns and societal benefits.
Key achievements in 2024 include Novo Holdings’ largest-ever investment in Asia with India’s Manipal Hospitals, a leader in affordable healthcare. Additionally, the company made its first planetary health investment in Asia by supporting AgNext Technologies in India, which uses artificial intelligence (AI) to improve food quality and safety. The opening of an expanded office in Shanghai further underscores Novo Holdings’ commitment to the region.
The company’s Year in Review also highlights milestones such as FDA clearance for Qureai’s lung nodule detection tool and strategic acquisitions by Manipal Hospitals and Medi Assist. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, stated, “In 2024, we advanced our mission of investing in innovation that improves lives through strengthening healthcare systems, advancing AI in diagnostics, and enabling more sustainable food production.”
Looking forward, Novo Holdings aims to continue expanding its regional platform and deepening partnerships to drive impactful solutions at the intersection of health science and sustainability. The full review is available on Novo Holdings’ website.
“`
